Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRESSA in Malignant Mesothelioma
NCT00787410Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2003
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of gefitinib in malignant mesothelioma, sponsored by AstraZeneca. Started Sep 2003; status: completed.
02
Drugs
03
Conditions
malignant mesothelioma
Beyond the preview
Go deeper on NCT00787410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00787410.